Camrelizumab plus chemo after stent for left bowel cancer
Part of Cancer, Digestive system, Injuries & trauma clinical trials.
This study tests whether adding camrelizumab (an immune therapy) to chemotherapy—after a stent is placed to open a blocked left-sided colon—improves outcomes. It’s meant for people whose cancer can still be removed with surgery after the blockage is treated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blockage in the left colon or upper rectum from suspected colon cancer, confirmed by scans
- Your tumor can be removed with surgery (it is resectable)
- You can sign informed consent
- Your general health is good enough for treatment (ECOG 0–1)
- Your blood counts and organ function are high enough for chemotherapy (blood cells, platelets, kidney, liver)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding the immunotherapy drug camrelizumab to standard chemotherapy before surgery for people with stage IIIA-IIIB non-small cell lung cancer. The goal is to see if this combination shrinks tumors more effectively before removal.
This trial tests adding immunotherapy to standard chemotherapy and targeted therapy for people with metastatic colorectal cancer that is MSS (microsatellite stable) and cannot be removed with surgery. It aims to see if this combination helps shrink tumors and improve outcomes.
This Phase 2 study looks at whether adding an immunotherapy medicine (camrelizumab) to standard chemotherapy after lung surgery can help prevent lung cancer from coming back. It is for people with stage IIA–IIIA non-small cell lung cancer who cannot use targeted (mutation-based) adjuvant therapy.
This trial tests a combination of an immunotherapy drug (camrelizumab) with chemotherapy and radiation to shrink advanced rectal cancer before surgery. The goal is to help more patients have successful surgery with complete tumor removal.
This trial tests if adding immunotherapy to standard chemotherapy and radiation before surgery helps shrink high-risk rectal cancer and prevent it from coming back. You may be a good fit if you have a specific type of advanced rectal cancer that hasn't spread to other parts of your body.
This study checks how well the immunotherapy drug camrelizumab works for people with advanced esophageal cancer outside of highly controlled trial settings. It may help doctors understand which patients benefit and how the treatment is used in everyday care.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.